Assessment of clinical end result guidelines in individuals treated with ravulizumab or efgartigimod. specialised MG centres receiving either C5IT (26 eculizumab, 80 ravulizumab) or efgartigimod (47 individuals) was carried out. Propensity score matching (PSM) was used to compare changes in
These studies demonstrate that hematopoiesis and neutrophil differentiation from human iPSCs recapitulates many features of embryonic hematopoiesis and neutrophil production in marrow, but reveals unexpected molecular signatures that may serve as a guide for enhancing iPSC hematopoiesis
These studies demonstrate that hematopoiesis and neutrophil differentiation from human iPSCs recapitulates many features of embryonic hematopoiesis and neutrophil production in marrow, but reveals unexpected molecular signatures that may serve as a guide for enhancing iPSC hematopoiesis. development of these